Treatment of pulmonary hypertension in congenital heart disease
Treatment of pulmonary hypertension in congenital heart disease
Treatment of pulmonary hypertension in congenital heart disease
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
Acute management <strong>of</strong> <strong>pulmonary</strong> <strong>hypertension</strong>2912. Cantor WJ, Harrison DA, Moussadji JS, Connelly MS, Webb GD, Liu P, McLaughl<strong>in</strong> PR, SiuSC Determ<strong>in</strong>ants <strong>of</strong> survival and length <strong>of</strong> survival <strong>in</strong> adults with Eisenmengersyndrome. Am J Cardiol. 1999 Sep 15;84(6):677-813. Beghetti M Congenital <strong>heart</strong> <strong>disease</strong> and <strong>pulmonary</strong> <strong>hypertension</strong>. Rev Port Cardiol.2004;23(2):273-81.14. Adpated from Badesch D, Abman SH, Simonneau G,Lewis J. Rub<strong>in</strong> LJ , McLaughli VVMedical Therapy for Pulmonary Arterial Hypertension Updated ACCP Evidence-BasedCl<strong>in</strong>ical Practice Guidel<strong>in</strong>es Chest 2007; 131:1917–1928.15. Atz AM, Adatia I, Lock JE, Wessel DL. Comb<strong>in</strong>ed effects <strong>of</strong> nitric oxide and oxygen dur<strong>in</strong>gacute <strong>pulmonary</strong> vasodilator test<strong>in</strong>g. J Am Coll Cardiol 1999; 33: 813-9.16. Opitz CF, Wensel R, Bettmann M, Schaffarczyk R, L<strong>in</strong>scheid M, Hetzer R, et al. Assessment<strong>of</strong> the vasodilator response <strong>in</strong> primary <strong>pulmonary</strong> <strong>hypertension</strong>. Eur Heart J 2003; 24: 356-6517. Limsuwan A, Khosithseth A, Wanichkul S, Khowsathit P. Aerosolized iloprost for <strong>pulmonary</strong>vasoreactivity test<strong>in</strong>g <strong>in</strong> children with long-stand<strong>in</strong>g <strong>pulmonary</strong> <strong>hypertension</strong> related to<strong>congenital</strong> <strong>heart</strong> <strong>disease</strong>. Catheter Cardiovasc Interv. 2009.18. Limsuwan A, Wanitkul S, Khosithset A, Attanavanich S, Samankatiwat P. Aerosolizediloprost for postoperative <strong>pulmonary</strong> hypertensive crisis <strong>in</strong> children with <strong>congenital</strong> <strong>heart</strong><strong>disease</strong>. Int J Cardiol. 2007.19. Hallioglu O, Dilber E, Alpay Celiker A. Comparison <strong>of</strong> Acute Hemodynamic Effects <strong>of</strong>Aerosolized and Intravenous Iloprost <strong>in</strong> Secondary Pulmonary Hypertension <strong>in</strong> ChildrenWith Congenital Heart Disease. Am J Cardiol 2003; 92: 1007–9.20. Sitbon O, Humbert M, Jaïs X, Ioos V, Hamid AM, Provencher S, Garcia G, Parent F, HervéP, Simonneau G. Long-term response to calcium channel blockers <strong>in</strong> idiopathic <strong>pulmonary</strong>arterial <strong>hypertension</strong>. Circulation. 2005;111:3105-3111.21. Outcome <strong>of</strong> cardiac surgery <strong>in</strong> <strong>congenital</strong> <strong>heart</strong> <strong>disease</strong> patients with <strong>pulmonary</strong><strong>hypertension</strong> : Thailand Experience 2005 : Abstract presentation at Shieng Hai ChildrenHospital symposium on critical <strong>in</strong> <strong>congenital</strong> <strong>heart</strong> <strong>disease</strong>.22. Smadja DM, Gaussem P, Mauge L, Israël-Biet D, Dignat-George F, Peyrard S (Circulat<strong>in</strong>gEndothelial Cells A New Candidate Biomarker <strong>of</strong> Irreversible Pulmonary HypertensionSecondary to Congenital Heart Disease Circulation. 2009;119:374-381.
Change language